The effects of bufadienolides on HER2 overexpressing breast cancer cells

被引：10
|
作者：
Wang, Tianjiao [1 ]
Mu, Lin [2 ]
Jin, Haifeng [1 ]
Zhang, Peng [1 ]
Wang, Yueyue [1 ]
Ma, Xiaochi [2 ]
Pan, Jinjin [1 ]
Miao, Jian [3 ]
Yuan, Yuhui [1 ]
机构：
[1] Dalian Med Univ, Ctr Canc, Inst Canc Stem Cell, Dalian, Peoples R China
[2] Dalian Med Univ, Coll Pharm, Dalian, Peoples R China
[3] Dalian Med Univ, Affiliated Hosp 2, Dept Gen Surg, Dalian, Peoples R China
来源：
TUMOR BIOLOGY | 2016年 / 37卷 / 06期
基金：
中国国家自然科学基金;
关键词：
Breast cancer; HER2; SRC-1; SRC-3; GROWTH-FACTOR-RECEPTOR; TAMOXIFEN RESISTANCE; TOAD VENOM; COACTIVATOR AIB1; ESTROGEN; ARENOBUFAGIN; SRC-3; PROLIFERATION; TRANSCRIPTION; MECHANISMS;
D O I：
10.1007/s13277-015-4381-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
HER2 is a proto-oncogene frequently amplified in human breast cancer, its overexpression is correlated with tamoxifen resistance and decreased recurrence-free survival. Arenobufagin and bufalin are homogeneous bufadienolides of cardiac glycosides agents. In this research, we studied the effects of arenobufagin and bufalin on cellular survival and proliferation of HER2 overexpressing breast cancer cells and the mechanism under the results including the direct effect on HER2 downstream pathways. Our results showed that arenobufagin and bufalin could significantly inhibit the proliferation and survival of HER2 overexpressing breast cancer cells, along with the declination of SRC-1, SRC-3, nuclear transcription factor E2F1, phosphorylated AKT, and ERK. And the combination of each bufadienolide in low dose with tamoxifen could significantly enhance the inhibitory effect of tamoxifen on HER2 overexpressing breast cancer cells. All above suggest that arenobufagin and bufalin may be potential therapy adjuvants for HER2 overexpressing breast cancer therapy.
引用
收藏
页码：7155 / 7163
页数：9
相关论文
共 50 条
  • [31] Trastuzumab - A review of its use in the treatment of metastatic breast cancer overexpressing HER2
    McKeage, K
    Perry, CM
    DRUGS, 2002, 62 (01) : 209 - 243
  • [32] Response to neoadjuvant chemotherapy in HER2 non-overexpressing breast cancer subtypes
    Ilie, S. M.
    Desmoulins, I.
    Hennequin, A.
    Coureche-Guillaume, K.
    Arnould, L.
    Nathalie, B.
    Bertaut, A.
    Ladoire, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [33] Extended survival in women with brain Metastases from HER2 overexpressing breast cancer
    Church, David N.
    Modgil, Ramayana
    Guglani, Sam
    Bahl, Amit
    Hopkins, Kirsten
    Braybrooke, Jeremy P.
    Blair, Peter
    Price, Chris G. A.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2008, 31 (03): : 250 - 254
  • [34] Proteomic analysis of breast cancer cell lines overexpressing the Her2/neu oncogene
    Fragkos-Livanios, L.
    Gartaganis, V.
    Samiotaki, M.
    Baxevanis, C. N.
    Panayotou, G.
    FEBS JOURNAL, 2008, 275 : 332 - 332
  • [35] Significant clinical benefits associated with lapatinib and capecitabine in HER2 overexpressing breast cancer
    Tokajuk, Piotr
    ONCOLOGY IN CLINICAL PRACTICE, 2011, 7 : A19 - A20
  • [36] TrastuzumabA Review of its Use in the Treatment of Metastatic Breast Cancer Overexpressing HER2
    Kate McKeage
    Caroline M. Perry
    Drugs, 2002, 62 : 209 - 243
  • [37] Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives
    Milani, A.
    Sangiolo, D.
    Montemurro, F.
    Aglietta, M.
    Valabrega, G.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1740 - 1748
  • [38] Successful targeting HER2 in heavily pretreated HER2-negative metastatic breast cancer patients presenting with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells
    Kurbacher, C. M.
    Quade, A.
    Eichler, C.
    Kunstmann, G.
    Herz, S.
    Kurbacher, J. A.
    Warm, M. R.
    CANCER RESEARCH, 2016, 76
  • [39] Long term effects of trastuzumab on cardiopulmonary and left ventricular function in women with HER2 overexpressing breast cancer
    Pituskin, E.
    Paterson, I.
    Ghosh, S.
    Mackey, J. R.
    Haykowsky, M. J.
    CANCER RESEARCH, 2016, 76
  • [40] Her2/neu Overexpressing Breast Cancer Patients Retain an Immunological Proficiency Compromised in Her2/neu-Negative Cases
    Simona, S. S. S.
    Muraro, E. M. E.
    Miolo, G. G. M.
    Martorelli, D. M. D.
    Turchet, E. T. E.
    Comaro, E. C. E.
    Talamini, R. T. R.
    Veronesi, A. V. A.
    Crivellari, D. C. D.
    Dolcetti, R. D. R.
    CANCER RESEARCH, 2010, 70
12345